PT - JOURNAL ARTICLE AU - Kumar, Ashutosh AU - Therrien, Nicole L. AU - Ogwuegbu, John I. AU - Lee, Jun Soo AU - Wall, Hilary K. AU - Flack, John M. AU - Jackson, Sandra L. TI - Trends in Prescription Fills for Blood Pressure-Elevating and Antihypertensive Medications, 2017–2023 AID - 10.1101/2024.11.14.24317362 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.14.24317362 4099 - http://medrxiv.org/content/early/2024/11/15/2024.11.14.24317362.short 4100 - http://medrxiv.org/content/early/2024/11/15/2024.11.14.24317362.full AB - Background Many medications can have blood pressure (BP)-elevating effects, which might negatively impact BP control among persons with hypertension. This study examines trends in prescription fills for BP-elevating and antihypertensive medications, individually and concurrently, among US individuals.Methods Quarterly trends of concurrent and individual fills for BP-elevating and antihypertensive medications were reported using the national sample from IQVIA’s Total Patient Tracker database, covering 94% of all retail prescription fills in the US. We identified 1,387 products containing BP-elevating medications and 240 products containing antihypertensive medications. Percentage change from Q1/2017 and average quarterly percent change from Joinpoint regression were used to present trends overall and by sex and age group (0–17, 18–44, 45–64, 65–74, and ≥75 years).Results During 2017–2023, fills remained stable for BP-elevating medications alone and increased for antihypertensive medication alone (9.5% increase; from 10.1% to 11.0%; p<0.001). Concurrent fills for antihypertensive and BP-elevating medications increased by 15.9% (from 5.4% to 6.2%; p<0.001). Prescription fills for BP-elevating medications were higher among adult women compared to men; among women aged 18 to 44 years, this was primarily due to the use of combined oral contraceptives. In Q4/2023, prescription fills for BP-elevating medications were most common among those aged 65–74 years (females=30.7% vs males = 20.4%).Conclusions These results provide the first national trends in concurrent prescription fills for BP-elevating and antihypertensive medications, indicating an increasing trend. Our findings might inform clinicians in their decision-making regarding medication selection for patients with hypertension.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were deidentified and no institutional board approval was required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study uses proprietary data from IQVIA. Request for data can be obtained from IQVIA.